| Literature DB >> 31199814 |
Mina Fujitani1, Takafumi Mizushige2, Fuminori Kawabata3, Keisuke Uozumi1, Machi Yasui1, Kohsuke Hayamizu4, Kenji Uchida1,5, Shinji Okada6, Bhattarai Keshab1, Taro Kishida1,7.
Abstract
The promotion of muscle recovery after immobilization is important to preserve an optimum health status. Here, we examined the effect of dietary Alaska pollack protein (APP) on skeletal muscle weight after atrophy induced by hind limb immobilization using plaster immobilization technique. Rat left limb was casted with a wetted plaster cast under anesthesia. After 2 weeks of feeding, the cast was removed and the rats were divided into three groups, namely, a baseline group, high-fat casein diet group, and high-fat APP diet group. After 3 weeks of feeding, the skeletal muscles (soleus, extensor digitorum longus [EDL], and gastrocnemius) were sampled. The estimated weight gains of soleus, gastrocnemius, and EDL muscle in the immobilized limbs were significantly larger in the rats fed with APP diet as compared with those fed with casein diet. In soleus muscle, dietary APP increased the expression of Igf1 and Myog genes in the immobilized limbs after the recovery period.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31199814 PMCID: PMC6570023 DOI: 10.1371/journal.pone.0217917
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Schedule of rat feeding during immobilization and recovery periods.
Left limb was immobilized at knee joint by a plaster and the rats were fed with high-fat casein diet for 2 weeks. After cast removal, five rats were sacrificed (baseline group). The rats were fed with either high-fat casein diet (Cas, n = 14) or high-fat APP diet (APP, n = 14) for the recovery period of 3 weeks and then sacrificed.
Primer sequences used in the present study.
| Genes | Sequences | Product size (bp) | NCBI ID | |
|---|---|---|---|---|
| sense | 80 | NM_001082477 | ||
| antisense | ||||
| sense | 94 | NM_019151 | ||
| antisense | ||||
| sense | 81 | NM_133521 | ||
| antisense | ||||
| sense | 80 | NM_080903 | ||
| antisense | ||||
| sense | 90 | NM_001106783 | ||
| antisense | ||||
| sense | 95 | NM_176079 | ||
| antisense | ||||
| sense | 91 | NM_017115 | ||
| antisense | ||||
| sense | 89 | NM_013172 | ||
| antisense | ||||
| sense | 206 | NM_017101 | ||
| antisense |
Igf1, insulin-like growth factor 1; Fbxo32, F-box protein 32; atrogin-1, atrophy gene-1; Trim63, tripartite motif-containing 63; MuRF1, muscle-specific RING finger protein-1; Myf5, myogenic factor 5; Myod1, myogenic differentiation 1; Myf6, myogenic factor 6; MRF4, myogenic regulatory factor 4; Ppia, peptidylprolyl isomerase A.
Fig 2Skeletal muscle weights in baseline group.
The weights of soleus, gastrocnemius, and extensor digitorum longus (EDL) muscles in unimmobilized (Unimmob) and immobilized (Immob) limbs from baseline group (n = 4–5) after the immobilization period are shown. Data are expressed as mean ± standard error of mean (SEM). Asterisks indicate significant differences as compared to unimmobilized limbs by Student’s paired t-test. **P < 0.01.
Fig 3Estimated skeletal muscle weight gains in immobilized limbs during recovery period.
The estimated weight gains of soleus, gastrocnemius, and extensor digitorum longus (EDL) muscles in immobilized limbs of high-fat casein diet group (Cas, n = 14) and high-fat APP diet group (APP, n = 14) during the recovery period are shown. The gains in skeletal muscle weight during the recovery period were estimated according to the following equation: Δskeletal muscle weight = (skeletal muscle weight at week 3 in Cas or APP group)—(average skeletal muscle weight at week 0 in baseline group). Data are expressed as mean ± standard error of mean (SEM). Statistical analysis was performed between Cas and APP group with the Student’s unpaired t-test. *P < 0.05, **P < 0.01.
Effects of dietary APP on food intake, protein intake, energy intake, body weight and skeletal muscle weight during the recovery period.
| Cas | APP | ||||||
|---|---|---|---|---|---|---|---|
| Food intake | g/3 w | 408 | ± | 6 | 377 | ± | 6 |
| Protein intake | g/3 w | 70 | ± | 1 | 66 | ± | 1 |
| Energy intake | MJ/3 w | 8.3 | ± | 0.1 | 7.7 | ± | 0.1 |
| Initial body weight | g | 258 | ± | 3 | 257 | ± | 3 |
| Final body weight | g | 402 | ± | 5 | 406 | ± | 5 |
| Body weight gain | g/3 w | 144 | ± | 4 | 149 | ± | 3 |
| Soleus muscle weight | g | 0.118 | ± | 0.003 | 0.13 | ± | 0.003 |
| Gastrocnemius muscle weight | g | 2.050 | ± | 0.04 | 2.316 | ± | 0.04 |
| EDL muscle weight | g | 0.167 | ± | 0.004 | 0.184 | ± | 0.004 |
Food intake, protein intake, energy intake, initial body weight, final body weight, body weight gain, and soleus, gastrocnemius and EDL muscle weight in immobilized limbs of high-fat casein diet group (Cas, n = 14) and high-fat APP diet group (APP, n = 14) during the recovery period are shown. Data are expressed as means ± standard errors (SEM). Statistical analysis was performed with the Student’s unpaired t-test.
**P < 0.01.
Effects of dietary APP on gene expression of the regulators involved in catabolism, anabolism, and myogenic process in immobilized limbs after recovery period.
| Cas | APP | ||||||
|---|---|---|---|---|---|---|---|
| target gene mRNA/ | |||||||
| (×10−1) | 2.90 | ± | 0.26 | 3.94 | ± | 0.36 | |
| (×10−3) | 0.83 | ± | 0.07 | 0.91 | ± | 0.11 | |
| (×10−2) | 0.36 | ± | 0.03 | 0.41 | ± | 0.05 | |
| (×10−2) | 0.40 | ± | 0.05 | 0.38 | ± | 0.04 | |
| (×10−2) | 1.10 | ± | 0.06 | 1.23 | ± | 0.09 | |
| (×10−3) | 4.75 | ± | 1.50 | 6.44 | ± | 1.02 | |
| (×10−1) | 0.50 | ± | 0.02 | 0.62 | ± | 0.04 | |
| (×10−1) | 0.61 | ± | 0.03 | 0.62 | ± | 0.05 | |
Igf1, Mstn (myostatin), Fbxo32 (atrogin-1), Trim63 (MuRF1), Myf5, Myod1 (MyoD), Myog (myogenin) and Myf6 (MRF4) gene expression of soleus muscle in immobilized limbs of high-fat casein diet group (Cas, n = 14) and high-fat APP diet group (APP, n = 14) after recovery period is shown. Data are expressed as means ± standard error of mean (SEM). Statistical analysis was performed with the Student’s unpaired t-test.
*P < 0.05. Igf1, insulin-like growth factor 1; Fbxo32, F-box protein 32; atrogin-1, atrophy gene-1; Trim63, tripartite motif-containing 63; MuRF1, muscle-specific RING finger protein-1; Myf5, myogenic factor 5; Myod1, myogenic differentiation 1; Myf6, myogenic factor 6; Myog, myogenin; MRF4, myogenic regulatory factor 4.